Evidence map›Paper›PMID 35343907›Full record

ArticleJMIR public health and surveillance2022

Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.

Simon de Lusignan, Ruby S M Tsang, Oluwafunmi Akinyemi, Jamie Lopez Bernal, Gayatri Amirthalingam, Julian Sherlock, Gillian Smith, Maria Zambon, Gary Howsam, Mark Joy

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Simon de LusignanUniversity of Oxford, Oxford, United Kingdom.ORCID 0000-0002-8553-2641
Ruby S M TsangUniversity of Oxford, Oxford, United Kingdom.ORCID 0000-0002-2520-526X
Oluwafunmi AkinyemiUniversity of Oxford, Oxford, United Kingdom.ORCID 0000-0003-0401-0145
Jamie Lopez BernalPublic Health England, London, United Kingdom.ORCID 0000-0002-1301-5653
Gayatri AmirthalingamPublic Health England, London, United Kingdom.ORCID 0000-0003-2078-0975
Julian SherlockUniversity of Oxford, Oxford, United Kingdom.ORCID 0000-0001-7427-1936
Gillian SmithPublic Health England, London, United Kingdom.ORCID 0000-0002-4257-0568
Maria ZambonPublic Health England, London, United Kingdom.ORCID 0000-0002-8897-7881
Gary HowsamRoyal College of General Practitioners, London, United Kingdom.ORCID 0000-0001-6699-5504
Mark JoyUniversity of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4974-3724
University of Oxford · GBPublic Health England · GBRoyal College of General Practitioners · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines.

objectiveWe aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season.

methodsWe carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency-specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere.

resultsA total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed.

conclusionsRoutine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.

Indexed as

Influenza, HumanInfluenza VaccinesHumansRetrospective StudiesSeasonsVaccinationInfluenza Vaccinesadverse events of interestcomputerized medical record systemsinfluenzainfluenza vaccinessentinel surveillance

Identifiers

PMID35343907
PMCPMC9002594
OpenAlexW3143551794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.